SCHEMBL10109185

SCHEMBL10109185

COc1cc(OC)cc(C2CCCC[C@@H]2O)c1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
ALDH1A1 P00352 3/20 0.41
TSHR P16473 1/20 0.41
SLC18A3 Q16572 1/20 0.39
AR P10275 3/20 0.37
LMNA P02545 2/20 0.37
KDM4E B2RXH2 2/20 0.35
POLB P06746 1/20 0.35
PKM P14618 1/20 0.35
NPC1 O15118 1/20 0.34
MAPT P10636 1/20 0.34
ATM Q13315 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
CA1 P00915 2/20 0.33
CA2 P00918 2/20 0.33
CA4 P22748 2/20 0.33
CA6 P23280 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL318180 1.00 MEN1 (0.41) MEN1KMT2AALDH1A1TSHRSLC18A3
SCHEMBL318321 0.96 ALDH1A1 (0.41) MEN1KMT2AALDH1A1TSHRSLC18A3
SCHEMBL318322 0.96 ALDH1A1 (0.41) MEN1KMT2AALDH1A1TSHRSLC18A3
SCHEMBL318320 0.96 ALDH1A1 (0.41) MEN1KMT2AALDH1A1TSHRSLC18A3
SCHEMBL9007090 0.83 HTR2C (0.51) ALDH1A1
SCHEMBL16885996 0.81 KDM1A (0.52) MEN1KMT2AALDH1A1SLC18A3AR
SCHEMBL4381314 0.81 KDM1A (0.52) MEN1KMT2AALDH1A1SLC18A3AR
SCHEMBL31549720 0.81 KDM1A (0.52) MEN1KMT2AALDH1A1SLC18A3AR
SCHEMBL318343 0.80 HTR2C (0.51)
SCHEMBL765244 0.80 HTR2C (0.51)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8093302-B2 Substituted tetralins as selective estrogen receptor-β agonists ELI LILLY AND COMPANY (US) 2012-01-10 US disclosed
US-8093302-B2 Substituted tetralins as selective estrogen receptor-β agonists ELI LILLY AND COMPANY (US) 2012-01-10 US disclosed
US-20100249075-A1 SUBSTITUTED TETRALINS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS ELI LILLY AND COMPANY (US) 2010-09-30 US disclosed
US-20100249075-A1 SUBSTITUTED TETRALINS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS ELI LILLY AND COMPANY (US) 2010-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249075-A1 SUBSTITUTED TETRALINS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS ESR2, ERLIN1, ESRRG MEN1 2698/4885KMT2A 2706/4885ALDH1A1 1735/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.